AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26597091 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrollment rate of clinics, providers, and patients
Number of subjects: 20
Study 26597180 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasotraline 4 or 8 mg/day
Number of subjects: 395
Study 26597180 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasotraline (various doses from 0.2 to 36 mg)
Number of subjects: 395
Study 26597180 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasotraline
Number of subjects: 395
Study 26597443 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab in combination with 5-fluorouracil (5FU) and mitomycin C (MMC) during chemoradiotherapy (CRT)
Number of subjects: 13
Study 26597443 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) 800 mg/m(2) on RT days 1-4 and 29-32 and mitomycin C (MMC) 8 mg/m(2) on days 1 and 29
Number of subjects: 13
Study 26597443 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard doses of cetuximab
Number of subjects: 13
Study 26597653 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mosquito repellent distribution scheme (2-weekly bottle exchange programme)
Number of subjects: 135
Study 26597824 — intervention group
Group type: EXPERIMENTAL
Intervention: OHyperT (orthostatic hypertension) group (n=275)
Number of subjects: 972
Study 26597824 — intervention group
Group type: COMPARATOR
Intervention: Orthostatic normotension group (n=540)
Number of subjects: 972
Study 26597824 — intervention group
Group type: COMPARATOR
Intervention: OHypoT (orthostatic hypotension) group (n=157)
Number of subjects: 972
Study 26597937 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational intervention providing information related to chronic low back pain in different formats.
Number of subjects: 0
Study 26597937 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment provided by family physician.
Number of subjects: 0
Study 26597976 — intervention group
Group type: EXPERIMENTAL
Intervention: General health checks
Number of subjects: 0
Study 26597976 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 26598545 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-PET/CT
Number of subjects: 56
Study 26598545 — intervention group
Group type: EXPERIMENTAL
Intervention: early FDG-PET/CT
Number of subjects: 56
Study 26598545 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HER2-PET/CT and FDG-PET/CT
Number of subjects: 56
Study 26599244 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI)
Number of subjects: 17
Study 26599344 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR mutation analysis
Number of subjects: 747
Study 26599344 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR active mutation analysis
Number of subjects: 747
Study 26599344 — intervention group
Group type: COMPARATOR
Intervention: Tobacco use analysis
Number of subjects: 747
Study 26599344 — intervention group
Group type: COMPARATOR
Intervention: Regional lymph nodes involvement analysis
Number of subjects: 747
Study 26599344 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status analysis
Number of subjects: 747
Study 26599819 — intervention group
Group type: EXPERIMENTAL
Intervention: NASH females
Number of subjects: 70
Study 26599819 — intervention group
Group type: COMPARATOR
Intervention: SS females
Number of subjects: 70
Study 26599819 — intervention group
Group type: COMPARATOR
Intervention: Caucasian women with SS
Number of subjects: 70
Study 26599819 — intervention group
Group type: COMPARATOR
Intervention: African American women with SS
Number of subjects: 70
Study 26600201 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic musculoskeletal pain
Number of subjects: 1100
Study 26600201 — intervention group
Group type: COMPARATOR
Intervention: Psychological wellbeing
Number of subjects: 1100
Study 26600201 — intervention group
Group type: COMPARATOR
Intervention: Depression
Number of subjects: 1100
Study 26600201 — intervention group
Group type: COMPARATOR
Intervention: Fatigue
Number of subjects: 1100
Study 26600201 — intervention group
Group type: COMPARATOR
Intervention: Insomnia syndrome
Number of subjects: 1100
Study 26600201 — intervention group
Group type: COMPARATOR
Intervention: Sleep quality
Number of subjects: 1100
Study 26601643 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 1162
Study 26601643 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC) as a covariate
Number of subjects: 1162
Study 26601643 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation analysis
Number of subjects: 1162
Study 26602013 — intervention group
Group type: EXPERIMENTAL
Intervention: NCI-MPACT assay
Number of subjects: 38
Study 26602014 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene 180 mg daily
Number of subjects: 44
Study 26602087 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured personal diabetes care
Number of subjects: 179
Study 26602087 — intervention group
Group type: COMPARATOR
Intervention: Routine diabetes care
Number of subjects: 179
Study 26602164 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating fibrocytes during acute exacerbation (V1)
Number of subjects: 54
Study 26602164 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating fibrocytes at 2 months after exacerbation (V2)
Number of subjects: 54
Study 26602164 — intervention group
Group type: EXPERIMENTAL
Intervention: High percentage of circulating fibrocytes during exacerbation (V1)
Number of subjects: 54
Study 26602164 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of fibrocytes at V2
Number of subjects: 54
Study 26602164 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrocytes collected from patients with COPD at V1
Number of subjects: 54
Study 26602164 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor (CXCR4 antagonist)
Number of subjects: 54
Study 26602219 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-Based Imaging Tests
Number of subjects: 0
Study 26602219 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 26602490 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine challenge testing (MCCT)
Number of subjects: 101
Study 26602490 — intervention group
Group type: COMPARATOR
Intervention: Exercise treadmill challenge (ETC)
Number of subjects: 101
Study 26602490 — intervention group
Group type: COMPARATOR
Intervention: Exercise treadmill challenge (ETC) with a cutoff level at 17% of forced expiratory volume in 1 second
Number of subjects: 101
Study 26603283 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung transplantation after ex vivo lung perfusion (EVLP)
Number of subjects: 10
Study 26603536 — intervention group
Group type: EXPERIMENTAL
Intervention: lanreotide Autogel 120 mg every 4 weeks
Number of subjects: 90
Study 26603828 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (30 mg/day for 7 days, then 60 mg/day for 4 weeks)
Number of subjects: 106
Study 26603828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 26603990 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 46
Study 26604330 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 111
Study 26604330 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Cancer
Number of subjects: 111
Study 26604330 — intervention group
Group type: EXPERIMENTAL
Intervention: OSAS
Number of subjects: 111
Study 26604330 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 111
Study 26605292 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisodamine
Number of subjects: 354
Study 26605292 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 354
Study 26605506 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of CD4 CD38 T cells
Number of subjects: 111
Study 26605506 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of CD8 HLA-DR T cells
Number of subjects: 111
Study 26605506 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CD4 CD38 HLA-DR T cells levels
Number of subjects: 111
Study 26605506 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-for-age Z scores (WAZ)
Number of subjects: 111
Study 26606398 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (MTX plus sulfasalazine plus hydroxychloroquine)
Number of subjects: 416
Study 26606398 — intervention group
Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 416
Study 26606398 — intervention group
Group type: COMPARATOR
Intervention: MTX plus etanercept
Number of subjects: 416
Study 26606867 — intervention group
Group type: EXPERIMENTAL
Intervention: self-complementary AAV [scAAV]2(Y444,500,730F)-P1ND4v2 at low dose (5 × 10(9) vg)
Number of subjects: 5
Study 26606867 — intervention group
Group type: EXPERIMENTAL
Intervention: self-complementary AAV [scAAV]2(Y444,500,730F)-P1ND4v2 at medium dose (2.46 × 10(10) vg)
Number of subjects: 5
Study 26606867 — intervention group
Group type: EXPERIMENTAL
Intervention: self-complementary AAV [scAAV]2(Y444,500,730F)-P1ND4v2
Number of subjects: 5
Study 26607424 — intervention group
Group type: EXPERIMENTAL
Intervention: EMA-approved dose
Number of subjects: 162
Study 26607424 — intervention group
Group type: COMPARATOR
Intervention: FDA-approved dose
Number of subjects: 162
Study 26607940 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 25
Study 26607940 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 25
Study 26607940 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RYGB and LAGB
Number of subjects: 25
Study 26607943 — intervention group
Group type: EXPERIMENTAL
Intervention: Top tertile of glycemic index (GI)
Number of subjects: 3363
Study 26607943 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher glycemic load (GL) values
Number of subjects: 3363
Study 26607943 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater GI in women
Number of subjects: 3363
Study 26607977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram-based adaptation of radiotherapy target volumes for ECE
Number of subjects: 27
Study 26607977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram-based adaptation of radiotherapy target volumes for SVI
Number of subjects: 27
Study 26607977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram-based adaptation of radiotherapy target volumes for LNI
Number of subjects: 27
Study 26607977 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with trial contouring protocol
Number of subjects: 27
Study 26607977 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with small bowel contouring
Number of subjects: 27
Study 26607977 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with dose constraints for target volumes
Number of subjects: 27
Study 26607977 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with dose constraints for OAR
Number of subjects: 27
Study 26607977 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute toxicity assessment
Number of subjects: 27
Study 26608460 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral flow test (LFT) with G12 monoclonal antibody for gluten immunogenic peptides (GIP)
Number of subjects: 58
Study 26608642 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially inappropriate prescribing (PIP) assessment tools applied to population-wide health administrative data
Number of subjects: 2000000
Study 26608976 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-MPH (18 mg, 36 mg, or 54 mg)
Number of subjects: 153
Study 26608976 — intervention group
Group type: COMPARATOR
Intervention: Non-ADHD group (control)
Number of subjects: 153
Study 26609168 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc deficiency risk assessment using stunting rates, dietary zinc intake, and plasma zinc concentration.
Number of subjects: 598
Study 26609168 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma zinc concentration (PZn) measurement.
Number of subjects: 598
Study 26609168 — intervention group
Group type: EXPERIMENTAL
Intervention: Height-for-age z scores (HAZ) measurement.
Number of subjects: 598
Study 26610172 — intervention group
Group type: EXPERIMENTAL
Intervention: Group drumming intervention, details on dosage and duration not available
Number of subjects: 0
Study 26610172 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 26611339 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis system (IPS) in conjunction with tube delivery system (TDS) for tube placement
Number of subjects: 70
Study 26612014 — intervention group
Group type: EXPERIMENTAL
Intervention: ledipasvir/sofosbuvir (LDV/SOF) (90 mg/400 mg) daily for 12 weeks
Number of subjects: 60
Study 26612014 — intervention group
Group type: EXPERIMENTAL
Intervention: ledipasvir/sofosbuvir (LDV/SOF) + GS-9451 (80 mg/day) daily for 6 weeks
Number of subjects: 60
Study 26612014 — intervention group
Group type: EXPERIMENTAL
Intervention: ledipasvir/sofosbuvir (LDV/SOF) + GS-9669 (500 mg twice daily) for 6 weeks
Number of subjects: 60
Study 26612014 — intervention group
Group type: COMPARATOR
Intervention: Recent drug use
Number of subjects: 60
Study 26612014 — intervention group
Group type: COMPARATOR
Intervention: Controlled psychiatric disease or symptoms of depression
Number of subjects: 60
Study 26612072 — intervention group
Group type: EXPERIMENTAL
Intervention: Autocalibrated semi-invasive pulse contour analysis (CIPFX)
Number of subjects: 65
Study 26612072 — intervention group
Group type: COMPARATOR
Intervention: Transpulmonary thermodilution (CITPTD)
Number of subjects: 65
Study 26612321 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant concurrent chemoradiotherapy with hematopoietical bone marrow sparing
Number of subjects: 35
Study 26612576 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-phasic injectable ceramic bone substitute (CERAMENT™ BONE VOID FILLER)
Number of subjects: 14
Study 26612701 — intervention group
Group type: COMPARATOR
Intervention: PPI (Proton Pump Inhibitors)
Number of subjects: 10116
Study 26612701 — intervention group
Group type: COMPARATOR
Intervention: H2 RA (H2-receptor antagonists)
Number of subjects: 10116
Study 26612701 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexposed infants
Number of subjects: 10116
Study 26612701 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI cohort
Number of subjects: 10116
Study 26612701 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 RA cohort
Number of subjects: 10116
Study 26612870 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg posaconazole (as tablets) once daily (twice daily on day 1) for up to 28 days
Number of subjects: 210
Study 26612873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesicular cidofovir (2.5-5 mg/kg in 50-100 mL of normal saline) administered via transurethral catheter after oral probenecid (2 g) for up to 2 h of dwell time.
Number of subjects: 6
Study 26612880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker implantation
Number of subjects: 281
Study 26612880 — intervention group
Group type: COMPARATOR
Intervention: No pacemaker (observed by ILR)
Number of subjects: 281
Study 26612880 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative tilt test (TT)
Number of subjects: 281
Study 26612880 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive tilt test (TT)
Number of subjects: 281
Study 26612880 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid sinus massage (CSM)
Number of subjects: 281
Study 26612979 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 220 mg once daily after switching from enoxaparin 40 mg for thromboprophylaxis
Number of subjects: 168
Study 26612979 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg for thromboprophylaxis
Number of subjects: 168
Study 26614268 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg once daily for 4 weeks
Number of subjects: 32
Study 26614807 — intervention group
Group type: COMPARATOR
Intervention: Gene expression signature consisting of LRRN3, SASH1, PALLD, RGL1, TNFRSF17, CDKN1C, IGJ, RRM2, ID3, SERPING1, FUCA1; measured in whole blood.
Number of subjects: 0
Study 26614807 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoke exposure in mice.
Number of subjects: 0
Study 26614807 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR-based assay derived from the gene signature.
Number of subjects: 0
Study 26614966 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 500 mg
Number of subjects: 30
Study 26614966 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 1000 mg
Number of subjects: 30
Study 26614966 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 2000 mg
Number of subjects: 30
Study 26615020 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ/veliparib
Number of subjects: 28
Study 26615020 — intervention group
Group type: COMPARATOR
Intervention: TMZ alone
Number of subjects: 28
Study 26615061 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment with a pharmacokinetic-guided dosing strategy, initial dose of 20 mg/kg oral dose.
Number of subjects: 0
Study 26615061 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic-guided dosing strategy
Number of subjects: 0
Study 26615402 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD: 55% fat/25% saturated fat/27% carbohydrate)
Number of subjects: 20
Study 26615402 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (LFD: 20% fat/8% saturated fat/62% carbohydrate)
Number of subjects: 20
Study 26615402 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (LFD)
Number of subjects: 20
Study 26615402 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD)
Number of subjects: 20
Study 26615402 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 20
Study 26615857 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 98
Study 26616030 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapy (GDMT) plus revascularization (percutaneous coronary intervention or coronary artery bypass graft surgery)
Number of subjects: 0
Study 26616030 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone
Number of subjects: 0
Study 26618098 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy (2 units)
Number of subjects: 20
Study 26618119 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuramis Deep
Number of subjects: 67
Study 26618119 — intervention group
Group type: COMPARATOR
Intervention: Restylane
Number of subjects: 67
Study 26618534 — intervention group
Group type: EXPERIMENTAL
Intervention: Small vessel disease (SVD) noted on baseline MRI
Number of subjects: 451
Study 26618534 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of SVD
Number of subjects: 451
Study 26618534 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without SVD)
Number of subjects: 451
Study 26619773 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment, dosage and duration not specified
Number of subjects: 0
Study 26619834 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat 400 mg plus bortezomib 1.3 mg/m(2)
Number of subjects: 7
Study 26620049 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg bid
Number of subjects: 156
Study 26620049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 26620200 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based telesonography for echocardiography
Number of subjects: 100
Study 26620200 — intervention group
Group type: COMPARATOR
Intervention: LCD monitor for echocardiography
Number of subjects: 100
Study 26620200 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based telesonography for abdominal ultrasonography
Number of subjects: 100
Study 26620200 — intervention group
Group type: COMPARATOR
Intervention: LCD monitor for abdominal ultrasonography
Number of subjects: 100
Study 26620715 — intervention group
Group type: EXPERIMENTAL
Intervention: F/B-EVAR
Number of subjects: 168
Study 26620715 — intervention group
Group type: COMPARATOR
Intervention: Self-expanding stents
Number of subjects: 168
Study 26621025 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing (N=15 patients, 8 caregivers)
Number of subjects: 41
Study 26621025 — intervention group
Group type: COMPARATOR
Intervention: Neutral writing (N=12 patients, 6 caregivers)
Number of subjects: 41
Study 26621025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol awakening response (CAR)
Number of subjects: 41
Study 26621395 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) and leucocyte counts assessment
Number of subjects: 226
Study 26621395 — intervention group
Group type: COMPARATOR
Intervention: Surgeons' initial diagnosis
Number of subjects: 226
Study 26621394 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal hysterectomy
Number of subjects: 501
Study 26621394 — intervention group
Group type: COMPARATOR
Intervention: Total hysterectomy
Number of subjects: 501
Study 26621580 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (up to 5 g daily)
Number of subjects: 30
Study 26622643 — intervention group
Group type: EXPERIMENTAL
Intervention: Belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide
Number of subjects: 1
Study 26624926 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous GG genotype of PSMD13 rs3817629
Number of subjects: 621
Study 26624926 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMD9 rs1043307
Number of subjects: 621
Study 26625169 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Smell Identification Test (BSIT)
Number of subjects: 183
Study 26625169 — intervention group
Group type: COMPARATOR
Intervention: Smell Identification Test (SIT)
Number of subjects: 183
Study 26625449 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation of 7000 IU/day
Number of subjects: 44
Study 26625449 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation of 4000 IU/day
Number of subjects: 44
Study 26625449 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (both doses)
Number of subjects: 44
Study 26626272 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor squeeze test (90° hip flexion)
Number of subjects: 382
Study 26626272 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI findings
Number of subjects: 382
Study 26626272 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of injured anatomical structure
Number of subjects: 382